TSXV •
Healthcare •
Biotechnology •
Quote as of 07/28/2026 15:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeTSXV
Market Capitalization13.32 mln
Float155 mln
Earnings Date08/28/2026
Relative Strength
94
/ 100
Top performer
Debt / Equity
-0.66
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Payout Ratio
0%
No payout
ROA
-443
Deeply negative
Business Description
Hemostemix Inc. is a Canadian biotechnology company based in Calgary that creates medical treatments using stem cells drawn from a patient's own blood. Its main product, ACP-01, has completed Phase II clinical trials targeting serious conditions such as blocked arteries, heart disease, and vascular dementia. The company is also working on a second treatment, NCP-01, which is in early testing for nerve pain and movement recovery.
